Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy
Author:
Publisher
Elsevier BV
Subject
Organic Chemistry,Drug Discovery,Pharmacology,General Medicine
Reference114 articles.
1. Tryptophan catabolism in cancer: beyond Ido and tryptophan depletion;Platten;Cancer Res.,2012
2. Cancer immunotherapy by targeting Ido1/TDO and their downstream effectors;Platten;Front. Immunol.,2014
3. Marine natural products and other derivatives as potent indoleamine 2,3-dioxygenase inhibitors;Delfourne;Mini Rev. Med. Chem.,2012
4. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase;Pilotte;Proc. Natl. Acad. Sci. U. S. A.,2012
5. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites;Harlin;Cancer Immunol. Immunother.,2006
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Discovery and binding mode of a small molecule inhibitor of the apo form of human TDO2;2024-01-09
2. Tryptophan metabolism enzymes are potential targets in ovarian clear cell carcinoma;Cancer Medicine;2023-12
3. Dual-target inhibitors based on COX-2: a review from medicinal chemistry perspectives;Future Medicinal Chemistry;2023-12
4. IDO1 facilitates esophageal carcinoma progression by driving the direct binding of NF-κB and CXCL10;Cell Death Discovery;2023-10-31
5. Research progress of STAT3-based dual inhibitors for cancer therapy;Bioorganic & Medicinal Chemistry;2023-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3